Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer-Reply

JAMA Oncol. 2019 Jan 1;5(1):118. doi: 10.1001/jamaoncol.2018.5739.

Authors

Val Gebski¹, Teppo Huttunen², Heikki Joensuu³

Affiliations

¹ National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² 4Pharma Ltd, Turku, Finland.
³ Department of Oncology, Helsinki University Hospital, Helsinki University, Helsinki, Finland.

PMID: 30520954
DOI: 10.1001/jamaoncol.2018.5739

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms*
Chemoradiotherapy
EGF Family of Proteins
Humans
Receptor, ErbB-2
Trastuzumab

Substances

EGF Family of Proteins
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab